Recruiting NCT06733766
Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ultrasound-guided thermal ablation.
- Who it may be relevant to
- Registry conditions: Recurrent Thyroid Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer: A Multicenter Study
Overview
To evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer
Detailed description
To evaluate and predict the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer by a multicenter study
Interventions
- Procedure ultrasound-guided thermal ablation
microwave ablation, radiofrequency ablation, laser ablation
Primary outcome measures
- rate of disease progression [Time frame: through study completion, an average of 6 months]
Secondary outcome measures (5)
- rate of complications [Time frame: 1 week]
- rate of volume reduction [Time frame: through study completion, an average of 6 months]
- rate of tumor disappearance [Time frame: through study completion, an average of 6 months]
- Tg level [Time frame: through study completion, an average of 6 months]
- rate of delayed surgery [Time frame: through study completion, an average of 1 year]
Eligibility criteria
Inclusion criteria
- patient received thyroidectomy for thyroid cancer
- recurrent lesions were pathologically proven to be malignant by core-needle biopsy or fine needle aspiration
- no evidence of distant metastases.
- follow-up period ≥12 months
Exclusion criteria
- coagulation disorder, serious heart, respiratory, liver, or renal failure
- dysfunction of the vocal cord on the opposite side
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Chinese PLA General Hospital — Beijing
Identifiers
NCT: NCT06733766 · 2024-657